Substance-Related Disorders
Recent clinical, regulatory, research and industry developments relating to this disease.
Role of Nanomedicine in Transforming Pharmacotherapy for Substance Use Disorder (SUD).
Targeting Neuroplasticity in Substance Use Disorders: Implications for Therapeutics.
Comorbidity of binge eating disorder and other psychiatric disorders: a systematic review.
Adolescent Psychedelic Use and Psychotic or Manic Symptoms.
Psychedelic therapy in depression and substance use disorders.
Dopamine Pharmacodynamics: New Insights.
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q4 2026.
Clinical MilestonesViewHide
- 2025-08-14GLP-1R Agonist Treatment for Opioid Use DisorderResults expected Q4 2026
- 2026-06-01ClinicalPhase 2a Double-Blind Placebo-Controlled Trial of Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use DisorderPrimary completion
- 2025-08-14ClinicalGLP-1R Agonist Treatment for Opioid Use DisorderResults expected Q4 2026
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Substance-Related Disorders25
- Hallucinogens7
- Mental Disorders7
- Behavior, Addictive3
- Deep Brain Stimulation2
- Habits2
- Motivation2
- Psychotherapy2
Leading journals6
- International journal of molecular sciences3
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology3
- JAMA network open2
- JAMA psychiatry2
- Addiction (Abingdon, England)1
- American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics1
Leading researchers8
- Johnson MW2
- Vermetten E2
- Aboyans V1
- Adams DR1
- Akan M1
- Albai O1
- Allen H1
- Andrieu S1
Affiliations (unnormalised)6
- Karolinska Institutet3
- ARQ National Psychotrauma Center2
- Leiden University Medical Center2
- School of Medicine2
- School of Psychology2
- "Federico II" University of Naples1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Substance-related disorders are disorders associated with substance use or abuse. The grounding frames them as a broad category that includes problematic patterns of use and addiction-related behaviors.
The grounding supports substance use or abuse as the proximate basis of the disorder category. It also indicates that addictive drugs can alter brain organization and that individual differences, psychiatric symptoms, and coping motives may contribute to vulnerability.
The literature describes addiction-related neuroadaptations in brain reward and incentive-motivation systems, including sensitization to drugs and drug-associated stimuli. It also emphasizes a shift from voluntary drug use toward compulsive drug-seeking, with involvement of prefrontal cortical inhibitory control, striatal mechanisms, extinction circuits, habits, and conditioned cues.
Psychiatric symptoms are described as increasing risk of dependence, and stress or negative mood can augment drug choice. The grounding also notes coping motives as a mediator of risk and highlights drug-associated Pavlovian-conditioned stimuli as contributors to drug seeking and relapse.
The supplied grounding supports psychotherapy-based approaches, including motivational interviewing, as a treatment modality for substance abuse. It also indicates drug therapy as a covered area, but does not provide enough detail to specify particular medication classes.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Disorders related to substance use or abuse.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.